57-Year-Old Woman Presented for Screening Mammography: Digital, A, and tomosynthesis, B, craniocaudal images showed 1.8 cm asymmetry (arrows) lateral left breast categorized as BI-RADS 0. C, Ultrasound left breast evaluation revealed normal fibroglandular tissue (arrow) believed to correlate with mammographic finding. D, Asymmetry effaced on rolled lateral craniocaudal imaging. Metallic BB marker noted at 12 o’clock position, anterior depth. Final assessment BI-RADS 1. Image courtesy of ARRS

57-Year-Old Woman Presented for Screening Mammography: Digital, A, and tomosynthesis, B, craniocaudal images showed 1.8 cm asymmetry (arrows) lateral left breast categorized as BI-RADS 0. C, Ultrasound left breast evaluation revealed normal fibroglandular tissue (arrow) believed to correlate with mammographic finding. D, Asymmetry effaced on rolled lateral craniocaudal imaging. Metallic BB marker noted at 12 o’clock position, anterior depth. Final assessment BI-RADS 1. Image courtesy of ARRS


January 17, 2022 — According to an article in ARRS’ American Journal of Roentgenology (AJR), radiologists should consider performing ultrasound (US) first for digital breast tomosynthesis (DBT)-recalled noncalcified masses.

“Omitting diagnostic mammography when US is negative has a low false-negative rate,” wrote lead researcher Jessica H. Porembka, M.D., from the University of Texas Southwestern Medical Center in Dallas. Noting that US alone is effective in diagnosing noncalcified masses recalled on screening tomosynthesis, “for asymmetries,” she explained further, “diagnostic mammography may be best without the need for additional US, while architectural distortions still warrant diagnostic mammography and US.”

Per the protocol of Porembka et. al’s HIPAA-compliant, IRB–approved prospective study, 399 women (mean age, 60 years) recalled for noncalcified lesions from screening DBT underwent initial diagnostic US from July 2017 to June 2019. Imaging decisions—determined via BI-RADS assessments and management recommendations, biopsy outcomes, and follow-up—were recorded using case reports filed on the day of the diagnostic evaluation.

Ultrasound alone without mammography adequately completed the diagnostic evaluation of 71.2% (306/430) of noncalcified lesions recalled from screening tomosynthesis, 93.7% (178/190) of recalled masses, and diagnosed 92.1% (35/38) of cancers, yielding a sensitivity of 94.9% for cancer diagnosis.

“A large number of screening tomosynthesis–detected noncalcified masses may be further evaluated with ultrasound alone, without compromising diagnostic sensitivity,” the authors of this AJR article reiterated.

For more information: www.arrs.org


Related Content

News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Artificial Intelligence

Nov. 25, 2025 – Medical imaging AI company Avicenna.AI has announced a strategic partnership with Ferrum, an AI ...

Time November 25, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
News | RSNA 2025

Nov. 3, 2025 — QT Imaging Holdings has announced that its chief medical officer, Elaine luanow, MD, will host a seminar ...

Time November 04, 2025
arrow
News | Breast Imaging

Oct. 28, 2025 — QT Imaging Holdings, Inc., a medical device company focused on radiation-free imaging technology, has ...

Time October 28, 2025
arrow
News | Women's Health

Oct. 16, 2025 — Vave Health has introduced VaveEd, a hub for supporting ultrasound learning and education, alongside ...

Time October 16, 2025
arrow
News | RSNA 2025

Oct. 7, 2025 – Clairity Inc., a leader in AI-based breast cancer risk prediction, will make five scientific ...

Time October 07, 2025
arrow
News | Mammography | Mayo Clinic

Early detection is key to breast cancer survival. But nearly half of all women in the U.S. have dense breast tissue ...

Time October 03, 2025
arrow
Subscribe Now